VEGFA Antibody - #DF7470

>>买3送1 进行中>>
(8)   (9)  
产品: VEGFA 抗体
货号: DF7470
描述: Rabbit polyclonal antibody to VEGFA
应用: WB IHC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Sheep, Rabbit, Dog
分子量: 27kDa; 27kD(Calculated).
蛋白号: P15692
RRID: AB_2839407

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Pig(100%), Bovine(88%), Horse(88%), Sheep(88%), Rabbit(100%), Dog(100%)
克隆:
Polyclonal
特异性:
VEGFA Antibody detects endogenous levels of total VEGFA.
RRID:
AB_2839407
引用格式: Affinity Biosciences Cat# DF7470, RRID:AB_2839407.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen; MGC70609; MVCD1; Vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular endothelial growth factor; Vascular permeability factor; VEGF A; Vegf; VEGF-A; VEGF120; Vegfa; VEGFA_HUMAN; VPF;

抗原和靶标

免疫原:
Uniprot:

P15692(VEGFA_HUMAN) >>Visit HPA database.

基因/基因ID:
VEGFA(7422)
表达:
P15692 VEGFA_HUMAN:

Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.

描述:
This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.
序列:
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species
Results
Score
Pig
100
Dog
100
Rabbit
100
Horse
88
Bovine
88
Sheep
88
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P15692 作为底物

Site PTM Type Enzyme

研究背景

功能:

Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).

细胞定位:

Secreted.
Note: VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a significant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. A higher level expression seen in pituitary tumors as compared to the pituitary gland.

亚基结构:

Homodimer; disulfide-linked. Also found as heterodimer with PGF (By similarity). Interacts with NRP1.

蛋白家族:

Belongs to the PDGF/VEGF growth factor family.

研究领域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

文献引用

1). Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs. Science Advances (PubMed: 33627421) [IF=13.6]

Application: WB    Species:    Sample: endothelial cells

Fig. 3. |The mechanism underlying how the MSN/miR-21-5p complex promotes angiogenesis. (A) A heatmap of selected proteins representing strongly altered signaling pathways in three datasets of endothelial cells treated with MSN/miR-NC or MSN/miR-21-5p complexes. (B) KEGG pathway analysis of both up- and down-regulated pathways in endothelial cells after MSN/miR-21-5p complex treatment. (C) Western blot analysis of changes in SPRY1, P-ERK1/2, P-FAK, P-p38, P-AKT, VEGFA, and PDGF-BB protein content alteration in endothelial cells after treatment with the MSN/miR-21-5p complex.
2). MicroRNA-934 facilitates cell proliferation, migration, invasion and angiogenesis in colorectal cancer by targeting B-cell translocation gene 2. Bioengineered (PubMed: 34699325) [IF=4.9]

Application: WB    Species: Human    Sample: HCT116 cells

Figure 6. miR-934 mediated cell proliferation, migration, invasion and angiogenesis in dependent with BTG2. HCT116 cells were transfected with BTG2 siRNAs (50 pmol) and control siRNA with/without miR-934 inhibitor (50 pmol). (a) The mRNA levels of BTG2 in HCT116 cells were detected by qRT-PCR. (b) Cell proliferation was analyzed using MTT assay after the transfection. (c) The migratory ability of HCT116 cells was determined by wound healing assay. Scale bar: 200 μm. (d) The invasive ability of HCT116 cells was assessed by transwell assay. Scale bar: 100 μm. (e) The tube formation ratio of HUVECs were analyzed by tube formation assay. Scale bar: 200 μm. (f) The protein levels of BTG2 and VEGF were detected by western-blot. Bars and error bars represent mean values and the corresponding SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
3). Integrating Metabolomics and Network Pharmacology to Explore the Mechanism of Xiao-Yao-San in the Treatment of Inflammatory Response in CUMS Mice. Pharmaceuticals (Basel, Switzerland) (PubMed: 38004472) [IF=4.6]

Application: IHC    Species: Mouse    Sample:

Figure 9 Immunohistochemistry (magnification 400×, n = 3) (a,c,d), RT-qPCR (e,f) and Western Blot (b,g,h) analysis of key targets. Data are presented as mean ± SD, n = 3 pre group. * p < 0.05, ** p < 0.01 compared with the control group, # p < 0.05, ## p < 0.01, compared with the CUMS group.

Application: WB    Species: Mouse    Sample:

Figure 9 Immunohistochemistry (magnification 400×, n = 3) (a,c,d), RT-qPCR (e,f) and Western Blot (b,g,h) analysis of key targets. Data are presented as mean ± SD, n = 3 pre group. * p < 0.05, ** p < 0.01 compared with the control group, # p < 0.05, ## p < 0.01, compared with the CUMS group.
4). Network Pharmacology Experiments Show That Emodin Can Exert a Protective Effect on MCAO Rats by Regulating Hif-1α/VEGF-A Signaling. ACS Omega (PubMed: 35811865) [IF=4.1]

Application: WB    Species: Rat    Sample:

Figure 9 Effects of emodin on VEGF-A expression in MCAO rats. (a,b) are typical images and quantitative histograms of immunohistochemistry of VEGF-A, respectively. A, B, C, and D represent normal group, sham group, model group, and emodin group, respectively. (c,d) represent electrophoretic images and quantitative histogram of VEGF-A, respectively. Data are presented as mean ± SEM; *P < 0.05, **P < 0.01 vs sham group; #P < 0.05, ##P < 0.01 vs model group.

Application: IF/ICC    Species: Rat    Sample:

Figure 13 Immunofluorescence images and quantitative analysis of VEGF-A and Hif-1α. (a,c) VEGF-A and GFAP fluorescence double co-localization and the relevant quantitative analysis. VEGF-A (green), GFAP (red), and DAPI (nuclei marker, blue). (b,d) Hif-1α and NeuN fluorescence double co-localization and the relevant quantitative analysis (200×). Data are presented as mean ± SEM; *P < 0.05, **P < 0.01 vs sham group; #P < 0.05, ##P < 0.01 vs model group.
5). Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations. Journal of Food Biochemistry (PubMed: 36121703) [IF=4.0]
6). LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression. BMC CANCER (PubMed: 35468741) [IF=3.8]

Application: WB    Species: Human    Sample: HCT116, DLD1, and CaCo-2 cells

Fig. 5LINC00022 promoted angiogenesis in CRC. After HCT116, DLD1, and CaCo-2 cells were infected with LINC00022 low expression lentivirus or high expression lentivirus, the level of VEGFA in the cell supernatant was detected by the detection kit (a); The mRNA and protein levels of VEGFA in HCT116, DLD1, and CaCo-2 cells were measured using qRT-PCR and Western blot, respectively (b and c); The number of cavity formation was calculated (d). Scale bar = 200 μm. Data were presented as mean ± standard deviation (SD). N = 3. **P < 0.01 and ***P < 0.001 vs Lv-anti-NC group or Lv-NC group. VEGFA, vascular endothelial growth factor A; qRT-PCR, quantitative Real-time PCR
7). Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy. PeerJ (PubMed: 31293831) [IF=2.7]

Application: IHC    Species: human    Sample: breast

Figure 7 Immunohistochemical detection of the expression of MIF and VEGFA in a breast cancer tissue microarray. (A, D) Negative expression (-) in cancer-adjacent normal breast tissue.
8). Screening of Immunosuppressive Factors for Identifying Breast Cancer Malignant Phenotypes Using mRNA Microarray Datasets.

Application: IHC    Species: Human    Sample: breast cancer

Figure 3 Immunohistochemical detection of MIF (Row 1) and VEGFA (Row 2) in breast cancer tissue microarray.(a) and (D), Negative expression in Cancer adjacent normal breast tissue. (b) and (e), Negative expression in Invasive ductal carcinoma. (c) and (f), Positive expression in Invasive ductal carcinoma.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.